Progressive Pulmonary Fibrosis
AVLNAvalyn PharmaCatalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for Pirfenidone (AP01) (Antifibrotic Therapy) in Progressive Pulmonary Fibrosis. The expected timing is based on the latest available company guidance and may change.
06/17/26:- MIST Ph2b enrolled 375 PPF patients. Topline data expected H2 2027. 08/12/26:- MIST Ph2b enrollment completed with 398 patients. ERS abstracts will be presented in September 2026. Topline data are expected in H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.